Sort   by:  
 Page size 
GenomicCGEMS Prostate Cancer GWAS - Stage 1 - PLCO

The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer genome-wide association study (GWAS) included genotyping approximately 550,000 SNPs (Phase 1A with HumanHap300 and Phase 1B HumanHap240, both from Illumina, San Diego, CA) in 1,172 prostate cancer patients and 1,157 controls...

phs000207 | dbGaP
GenomicsCancer Genetic Markers of Susceptibility (CGEMS) Breast Cancer Genome-Wide Association Study (GWAS) - Primary Scan (Stage 1) - Nurses' Health Study

The Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer genome-wide association study (GWAS) included genotyping 528,173 SNPs (Illumina HumanHap550) in 1,145 postmenopausal women of European ancestry with invasive breast cancer and 1,142 controls from the Nurses' Health Study (...

phs000147.v1.p1 | EGA
GenomicsCancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer Genome-Wide Association Study (GWAS) - Primary Scan (Stage 1) - PLCO Screening Trial

The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer genome-wide association study (GWAS) included genotyping approximately 550,000 SNPs (Phase 1A with HumanHap300 and Phase 1B HumanHap240, both from Illumina, San Diego, CA) in 1,172 prostate cancer patients and 1,157 controls...

phs000207.v1.p1 | EGA
GenomicDCEG Imputation Reference Dataset

We have built a new resource for imputation of SNPs for existing and future genome-wide association studies (GWAS), known as the Division of Cancer Epidemiology and Genetics (DCEG) Reference Set. The first build of the data set includes 728 cancer-free individuals of European descent from...

phs000396 | dbGaP
GenomicsGlioma GWAS summary statistics
Meta-analysis association statistics from case-control analysis (includes imputed SNPs)
EGAD00010001657 | EGA
GenomicsSummary statistics from genome-wide association study in glioma of 12,488 cases and 18,169 controls.
Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,488 cases and 18,169 controls. We identified five ...
EGAS00001003372 | EGA
GenomicsGlioma GWAS summary statistics DAC
Data Access Committee EGAC00001001116
EGAC00001001116 | EGA
GenomicsA Genome-Wide Association Study of Lung Cancer Risk

Three genetic loci for lung cancer risk have been identified by genome-wide association studies (GWAS), but inherited susceptibility to specific histologic types of lung cancer is not well established. We conducted a GWAS of lung cancer and its major histologic types genotyping 515,922 single n...

phs000336.v1.p1 | EGA
GenomicsCohort-Based Genome-Wide Association Study of Glioma (GliomaScan)

We conducted a new independent GWAS of adult glioma using 1,856 cases and 4,955 controls from 14 cohort studies belonging to the Cohort Consortium, 3 case-control studies, and 1 population-based case only study. Cases were newly diagnosed glioma [ICDO-3 codes 9380-9480 or equivalent], and control...

phs000652.v1.p1 | EGA
GenomicsGenome wide association study for Bladder Cancer Risk

This study funded by the National Cancer Institute (NCI) involves conducting a genome-wide association study of common genetic variants to identify markers of susceptibility to bladder cancer.

This bladder GWAS has led to the discovery of three novel regions in the genome associated with...

phs000346.v1.p1 | EGA
Sort   by:  
 Page size